Abstract | BACKGROUND/AIMS:
Traditional Chinese medicine (TCM) has been used in clinical practice for thousands of years and has accumulated considerable knowledge concerning the in vivo efficacy of targeting complicated diseases. TCM formulae are a mixture of hundreds of chemical components with multiple potential targets, essentially acting as a combination therapy of multi-component drugs. However, the obscure substances and the unclear molecular mechanisms are obstacles to their further development and internationalization. Therefore, it is necessary to develop new modern drugs based on the combination of effective components in TCM with exact clinical efficacy. In present study, we aimed to detect optimal ratio of the combination of effective components based on Sheng-Mai-San for myocardial ischemia. METHODS: RESULTS: The optimized combination GRS (G: 6 mg/kg, R: 0.75 mg/kg, S: 6 mg/kg) obtained by experimental screening exhibited a significant protective effect on myocardial ischemia injury, as evidenced by decreased myocardium infarct size, ameliorated histological features, decreased myocardial myeloperoxidase (MPO) and malondiadehyde (MDA), calcium overload, and decreased serum lactate dehydrogenase (LDH), creatine kinase MB isoenzyme (CK-MB), cardiac troponin I ( cTn-I) activity. In addition, the interactions of three components in combination GRS were also investigated. The combination, compared to G, R and S, could significantly reduce the concentration of serum CK-MB and cTn-I, and decrease myocardial infarct size, which demonstrated the advantages of this combination for myocardial ischemia. CONCLUSION: Our results demonstrated that the optimized combination GRS could exert significant cardioprotection against myocardial ischemia injury with similar effect compared to Sheng Mai preparations, which might provide some pharmacological evidences for further development of new modern Chinese drug for cardiovascular diseases basing on traditional Chinese formula with affirmative therapeutic effect.
|
Authors | Fang Li, Xiao-Xue Fan, Chun Chu, Yu Zhang, Jun-Ping Kou, Bo-Yang Yu |
Journal | Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
(Cell Physiol Biochem)
Vol. 45
Issue 4
Pg. 1455-1471
( 2018)
ISSN: 1421-9778 [Electronic] Germany |
PMID | 29466787
(Publication Type: Journal Article)
|
Copyright | © 2018 The Author(s). Published by S. Karger AG, Basel. |
Chemical References |
- Cyclooctanes
- Drug Combinations
- Drugs, Chinese Herbal
- Ginsenosides
- Lignans
- Pituitary Hormones, Posterior
- Polycyclic Compounds
- Spirostans
- Troponin I
- fructus schizandrae, radix ginseng, radix ophiopogonis drug combination
- ginsenoside Rb1
- ruscogenin
- L-Lactate Dehydrogenase
- Creatine Kinase, MB Form
- schizandrin
- Isoproterenol
|
Topics |
- Animals
- Creatine Kinase, MB Form
(blood)
- Cyclooctanes
(therapeutic use)
- Disease Models, Animal
- Drug Combinations
- Drugs, Chinese Herbal
(therapeutic use)
- Ginsenosides
(therapeutic use)
- Heart
(drug effects)
- Isoproterenol
(toxicity)
- L-Lactate Dehydrogenase
(blood)
- Lignans
(therapeutic use)
- Medicine, Chinese Traditional
- Mice
- Mice, Inbred C57BL
- Mice, Inbred ICR
- Myocardial Infarction
(pathology)
- Myocardial Ischemia
(chemically induced, drug therapy, mortality, pathology)
- Myocardial Reperfusion Injury
(pathology)
- Myocardium
(metabolism, pathology)
- Pituitary Hormones, Posterior
(toxicity)
- Polycyclic Compounds
(therapeutic use)
- Spirostans
(therapeutic use)
- Troponin I
(blood)
|